Wilterding Mark 4

What Happened

• Mark Wilterding, Chief Financial Officer of RxSight, received two equity awards on January 12, 2026: a grant covering 258,770 derivative shares (stock option award) and a restricted stock unit (RSU) award covering 163,528 RSUs. Both awards are reported with an acquisition price of $0 (i.e., compensation grants, not purchases).

Key Details

• Transaction date: January 12, 2026; Form 4 filed January 30, 2026 (filed well after the typical two-business-day reporting window).
• Award amounts: 258,770 (option-style derivative) and 163,528 RSUs; filing shows $0 paid on grant.
• Shares owned after transaction: not specified in the provided filing data.
• Footnotes / vesting:
  • F1 (option): 25% vests on the one-year anniversary of the Vesting Commencement Date (January 11, 2027), remainder vests monthly over the next three years (fully vested four years from Jan 11, 2026).
  • F2: Each RSU equals a contingent right to receive one share of common stock.
  • F3 (RSU vesting): 1/8 of the RSUs vest on February 28, 2026, then 1/8 every six months (last day of Feb and Aug) over four years.
• No indication of a 10b5-1 plan, cashless exercise, sale, or tax-withholding disposition in the reported transactions.

Context

• These are compensation awards (an option grant and RSUs). Options grant the right to buy shares in the future subject to vesting and any exercise price/terms; RSUs convert to shares if and when they vest. Because these are grants (not open-market purchases or sales), they reflect compensation decisions rather than an immediate insider market trade. The late filing may affect timely transparency but does not change the award terms disclosed.